Research Scientist - RNA Biology
Dana-Farber Cancer Institute/Harvard Medical School
450 Brookline Avenue, Harvard Institute of Medicine (HIM342), Boston, MA02115
Email: firstname.lastname@example.org, Cell phone: 1-857-333-9586
A. RESEARCH EXPERIENCE
Research Fellow: Dana-Farber Cancer Institute/Harvard Medical School, 2011-present
- Expert in epigenetic field-Chromatin Immunoprecipitation(ChIP),chromatin remodeling assay, Chromatin assemble,octamer purification etc.
- Experienced recombinant protein (ATPase-chromatin remodeling factor) expression and purification, using Bac-to-Bac baculovirus expression system (FLAG-tagged fusion) in insect sf9 cell and using pET system in bacteria. Perform Size-exclusion chromatography-HiLoad Superdex 200 column by AKTA purifier for proteins purity.
- Actively involved collaboration cancer drug development project with Novartis. Validating inhibitors as 2nd screening (Novartis’s primary small molecule) use Epigenetics Biochemistry Assay-ATPase assay and Restriction Enzyme Accessibility Assay (REA)
- Developing HARP/SMARCAL1 inhibitors by High-Throughput screening use small molecule compound Libraries (ICCB Longwood Facility).
- Recombinant Viruses generation use POZ vector in HEK293 cell.
- Supervision and training of other lab members in their own projects
- Published my research project on Journal of Biological Chemistry and PLoS One regarding CHD5 protein unique function on Chromatin and in vivo cell line.
- Developed high speed chromatin remodeling assay [patent]
Assistant Professor: Niigata University School of Medicine/Japan, 2007-2010
To identify susceptibility genes for endometriosis in Japanese women, performed gnenome-wide association (GWA) analysis using two case- control cohorts genotyped with Affimetrix Genome-Wide Humen SNP Array 6.0.
PHD: Molecular Cell Biology/Niigata University/Japan, 2003-2007
Identified Receptor tyrosine kinase, discoidin domain receptor1(DDR1) as potential biomarker and molecular target for advanced ovarian cancer.
MD: Medicine/Yanbian University School of Medicine/China, 1997—2002
In the first 4 years, took foundational coursework in the practice of medicine, bodily systems and diseases. During the last year training program, rotated through various hospital specialty departments and gained experience in patient care under faculty supervision.
B. EDUCATION AND TRAINING
Research Fellow - Dana-Farber Cancer Institute, Boston USA; 2011--present
Assistant Professor – Niigata University School of Medicine, Japan; 2007-2010
PhD – Niigata University School of Medicine, Japan; 2003-2007
MD –Yanbian University School of Medicine, China; 1997-2002
C. SKILLS SUMMARY
1. Enzyme-based assay: 1) Restriction Enzyme Accessibility Assay (REA)
2) Micrococcal Nuclease Sensitivity Assay
3) Nucleosome Sliding Assay
4) ATPase Assay
5) DNA binding Assay (gel shift)
2. Chromatin Assembly in vitro; histones and octamer purification;
3. Size exclusion chromatography – AKTA;
Anti-tumor drug development:
1) Recombinant protein purification (especially big size of protein purification)
2) Assay development for high throughput anti-tumor drug screening;
3) variety cancer cells culture
Molecular biology Technique:
1) Chromatin Immunoprecipitation(ChIP), IP;
2) siRNA/shRNA, DNA and RNA transfection
3) DNA cloning, PCR, RT-PCR, qPCR;
4) IHC, Immunofluoresence, Mass Spectrometry;
Chromatin Remodeling Activity Assays and Uses Thereof (pending)
-Dana Farber Cancer Institute
Epigenetics - ATP dependent protein’s functional study
l Quan J, Adelmant G, Marto JA, Look AT, Yusufzai T (2014) “ The chromatin remodeling factor CHD5 is a transcriptional repressor of WEE1.” PLoS One 9(9).
l Quan J, Yusufzai T (2014) “The tumor suppressor chromodomain helicase DNA-binding protein 5 (CHD5) remodels mucleosomes by unwrapping.” J Biol Chem 289(30):20717-26.
l Quan J, Yusufzai T (2014) “HARP preferentially co-purifies with RPA bound to DNA-PK and blocks RPA phosphorylation.” Epigenetics 9(5):693-7.
Genome-Wide Association (GWA) Analysis study
l Yoshihara K, Tajima A, Adachi S, Quan J, Sekine M, Kase H, Yahata T, Inoue I, Tanaka K(2011) “Germline copy number variations in BRCA1-associated ovarian cancer patients.” Genes Chromosomes Cancer 50(3):167-77.
l Adachi S, Tajima A, Quan J, Haino K, Yoshihara K, Masuzaki H, Katabuchi H, Ikuma K, Suginami H, Nishida N, Kuwano R, Okazaki Y, Kawamura Y, Sasaki T, Tokunaga K, Inoue I, Tanaka K(2010) “Meta-analysis of genome-wide association scans for genetic susceptibility to endometriosis in Japanese population.” J Hum Genet 55(12):816-21.
Gynecological cancer study
l Banzai C, Nishino K, Quan J, Yoshihara K, Sekine M, Yahata T, Tanaka K (2014) “Promoter methylation of DAPK1, FHIT, MGMT and CDKN2A genes in cervical carcinoma.” Int J Clin Oncol 19(1):127-32.
l Quan J, Yahata T, Adachi S, Yoshihara K, Tanaka K(2011) “Identification of receptor tyrosine kinase, discoidin domain receptor 1 (DDR1), as a potential biomarker for serous ovarian cancer.” Int J Mol Sci 12(2):971-82.
l Ashizawa N, Yahata T, Quan J, Adachi S, Yoshihara K, Tanaka(2010) “Serum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects” Gynecol Oncol 119(1):65-9.
l Yamada K, Fujita K, Quan J, Sekine M, Kashima K, Yahata T, Tanaka K(2010) “Increased apoptosis of germ cells in patients with AZFc deletions.” J Assist Reprod Genet 27(6):293-7.
l Quan J, Yahata T, Tamura N, Nagata H, Tanaka K(2009) “Relationship between single nucleotide polymorphisms in CYP1A1 and CYP1B1 genes and the bone mineral density and serum lipid profiles in postmenopausal Japanese women taking hormone therapy.” Menopause 16(1):171-6
l Obata H, Yahata T, Quan J, Sekine M, Tanaka K(2006) “Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer.” Anticancer Res 26(3B):2227-32.
l Kurabayashi T, Yahata T, Quan J, Tanaka K(2006) “Association of polymorphisms in the beta2 and beta3 adrenoceptor gene with polycystic ovary syndrome.” J Reprod Med 51(5):389-93.